Spots Global Cancer Trial Database for A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Official Title: A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Study ID: NCT02857426
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
City Of Hope Medical Center, Duarte, California, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Columbia University, New York, New York, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Baylor Research Institute, Dallas, Texas, United States
Swedish Medical Center, Seattle, Washington, United States
Instituto Do Cancer Mae De Deus / Cor Hospital Mae De Deus, Porto Alegre, Rio Grande Do Sul, Brazil
Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Sao Paulo, Brazil
Hospital Das Clinicas - Fmusp, Sao Paulo, , Brazil
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
CHU de Quebec, Quebec, , Canada
I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze, Praha 2, , Czechia
Local Institution, Bordeaux, , France
Local Institution, Caen, , France
Local Institution, La Tronche, , France
Local Institution, Lille Cedex, , France
Local Institution, Paris cedex 13, , France
Centre Hospitalier Lyon Sud - UPCO, Pierre Benite, , France
Local Institution, Rennes Cedex 9, , France
Local Institution, St. Cloud, , France
Local Institution, Tours Cedex 9, , France
Klinikum Stuttgart, Stuttgart, , Germany
Local Institution, Hong Kong, , Hong Kong
Local Institution, Budapest, , Hungary
Belgyogyaszati Onkologia OOI, Budapest, , Hungary
Local Institution, Debrecen, , Hungary
Local Institution, Haifa, , Israel
Local Institution, Jerusalem, , Israel
Local Institution, Petah Tikva, , Israel
Local Institution, Tel Aviv, , Israel
Irccs Ospedale S. Raffaele, Milano, , Italy
Fondazione Policlinico Universitario A. Gemelli, Roma, , Italy
Istituto Clinico Humanitas, Rozzano (milano), , Italy
Local Institution, Nagoya, Aichi, Japan
Local Institution, Fukuoka-shi, Fukuoka, Japan
Local Institution, Hidaka-shi, Saitama, Japan
Local Institution, Chuo-ku, Tokyo, Japan
Local Institution, Kotoku, Tokyo, Japan
Local Institution, Mitaka-shi, Tokyo, Japan
Local Institution, Yamagata, , Japan
Local Institution, Moscow, , Russian Federation
Local Institution, Singapore, , Singapore
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
